Citadel Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-3,662
| Closed | -$15.4K | – | 15798 |
|
|
2023
Q1 | $15.4K | Sell |
3,662
-47,649
| -93% | -$247K | ﹤0.01% | 13255 |
|
|
2022
Q4 | $308K | Sell |
51,311
-439,486
| -90% | -$2.4M | ﹤0.01% | 9260 |
|
|
2022
Q3 | $2.86M | Sell |
490,797
-328,777
| -40% | -$2.05M | ﹤0.01% | 4899 |
|
|
2022
Q2 | $4.89M | Buy |
819,574
+717,668
| +704% | +$3.67M | ﹤0.01% | 3829 |
|
|
2022
Q1 | $476K | Buy |
101,906
+79,790
| +361% | +$238K | ﹤0.01% | 9508 |
|
|
2021
Q4 | $55K | Sell |
22,116
-47,557
| -68% | -$116K | ﹤0.01% | 13200 |
|
|
2021
Q3 | $205K | Buy |
+69,673
| New | +$190K | ﹤0.01% | 11947 |
|
|
2021
Q2 | – | Sell |
-211,206
| Closed | -$506K | – | 15032 |
|
|
2021
Q1 | $615K | Buy |
211,206
+189,165
| +858% | +$618K | ﹤0.01% | 9238 |
|
|
2020
Q4 | $71K | Buy |
+22,041
| New | +$73.3K | ﹤0.01% | 10413 |
|
|
2020
Q2 | – | Sell |
-29,289
| Closed | -$27K | – | 10966 |
|
|
2020
Q1 | $27K | Buy |
+29,289
| New | +$33.6K | ﹤0.01% | 9225 |
|
|
2019
Q1 | – | Sell |
-74,395
| Closed | -$78.3K | – | 10383 |
|
|
2018
Q4 | $55K | Buy |
74,395
+30,126
| +68% | +$49.5K | ﹤0.01% | 8474 |
|
|
2018
Q3 | $96K | Buy |
44,269
+18,489
| +72% | +$45.8K | ﹤0.01% | 8593 |
|
|
2018
Q2 | $129K | Buy |
+25,780
| New | +$113K | ﹤0.01% | 8130 |
|
|
2018
Q1 | – | Sell |
-11,418
| Closed | -$31K | – | 9237 |
|
|
2017
Q4 | $31K | Buy |
+11,418
| New | +$33.5K | ﹤0.01% | 7766 |
|
|
2017
Q1 | – | Sell |
-6,696
| Closed | -$27K | – | 8546 |
|
|
2016
Q4 | $27K | Buy |
+6,696
| New | +$27.8K | ﹤0.01% | 7024 |
|
|
2016
Q2 | – | Sell |
-12,987
| Closed | -$69K | – | 7960 |
|
|
2016
Q1 | $69K | Buy |
12,987
+8,817
| +211% | +$70.5K | ﹤0.01% | 6167 |
|
|
2015
Q4 | $51K | Buy |
4,170
+3,406
| +446% | +$45.5K | ﹤0.01% | 7306 |
|
|
2015
Q3 | $11K | Buy |
+764
| New | +$13.2K | ﹤0.01% | 8456 |
|
|
2015
Q2 | – | Sell |
-91,302
| Closed | -$1.76M | – | 9499 |
|
|
2015
Q1 | $1.65M | Buy |
91,302
+16,158
| +22% | +$364K | ﹤0.01% | 3319 |
|
|
2014
Q4 | $1.77M | Buy |
75,144
+73,219
| +3,804% | +$1.69M | ﹤0.01% | 3051 |
|
|
2014
Q3 | $47K | Buy |
1,925
+1,715
| +817% | +$44.6K | ﹤0.01% | 6946 |
|
|
2014
Q2 | $6K | Sell |
210
-61,737
| -100% | -$1.86M | ﹤0.01% | 7712 |
|
|
2014
Q1 | $2.11M | Buy |
61,947
+59,687
| +2,641% | +$2.04M | ﹤0.01% | 2605 |
|
|
2013
Q4 | $43K | Buy |
2,260
+1,157
| +105% | +$21.1K | ﹤0.01% | 6135 |
|
|
2013
Q3 | $18K | Buy |
+1,103
| New | +$12.8K | ﹤0.01% | 6295 |
|
Other funds holding CTIC
Citadel Advisors's CTIC Position: Q2 2023 in Review
Citadel Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 3,662 shares — an estimated $15.4K sold.
Citadel Advisors first reported a position in CTIC in Q3 2013 and held it in 25 quarters. The position peaked at $4.89M in Q2 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- Citadel Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 3,662 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $15.4K.
- Citadel Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2013 and held it in 25 quarters.
- Citadel Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $4.89M in Q2 2022.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.